Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza virus split vaccine (Shanghai Institute of Biological Products)
- Development stage
- Unknown
- Lead developer
- Shanghai Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent influenza virus split vaccine developed by the Shanghai Institute of Biological Products (SIBP) is an inactivated, split-virion vaccine designed for the prevention of seasonal influenza. It contains hemagglutinin antigens from four distinct influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). By targeting the hemagglutinin protein, the vaccine induces the production of neutralizing antibodies that prevent viral entry into host cells. It is typically administered via intramuscular injection and has been evaluated in various pediatric populations, including children aged 6 months to 8 years, to ensure safety and immunogenicity across different dosing regimens.
- Other names
- SIBP quadrivalent influenza vaccineShanghai Institute of Biological Products quadrivalent influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent influenza virus split vaccine (Shanghai Institute of Biological Products).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza virus split vaccine (Shanghai Institute of Biological Products).